KING OF PRUSSIA, PA.— July 25, 2016 — Genomind, a personalized medicine company advancing mental healthcare through genetic testing, has been named one of the best places to work in health care by Modern Healthcare magazine.
The magazine “honors workplaces throughout the healthcare industry that empower their employees to provide patients and customers with the best possible care, products and services.”
“We are honored to receive this recognition from such a respected publication in our industry. Our associates work hard every day to provide genetic test results that can help patients get better. We are proud of the work we do and strive to be an employer of choice,” says Genomind’s CEO and President Michael Koffler.
“Building a workplace culture of engagement isn’t easy, especially in today’s high-stress health care environment, where every organization is under intense pressure to improve quality and safety while reducing costs,” says Merrill Goozner, editor, Modern Healthcare. “The firms honored as best places to work are leading the way to a better healthcare system.”
For the ninth year, Modern Healthcare’s “Best Places to Work in Healthcare” has partnered with the Best Companies Group on the assessment process, which includes an extensive employee survey.
This honor comes on top of another important milestone: the 80,000th patient has received results from the company’s Genecept Assay®, a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. Genecept is an easily administered cheek swab test that analyzes key genes, selected based on the critical examination of hundreds of studies showing that variations in these genes can inform treatment decisions in psychiatry.
Research has found 87 percent of patients demonstrated a clinically measurable improvement with treatment guided by the Genecept Assay. It also reported improvement in 91 percent of patients who had previously failed at least two medications.
The Genecept Assay is available for use by any licensed and prescribing clinician. Patients should discuss with their clinician whether the Genecept Assay test is right for them. Patients should have their clinician contact Genomind directly to order test kits and/or to receive more information about testing.
To find out more information about employment at Genomind, please visit: https://genomind.com/careers/.
Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com.
About the Genecept Assay®
The Genecept Assay® is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, post-traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacogenomic consultation. Learn more at www.genomind.com
Marketing Manager, Genomind